Date: 2016-03-01
Type of information: Production agreement
Compound: oncology monoclonal antibodies
Company: JHL Biotech (Taiwan) Affinita Biotech (USA - CA)
Therapeutic area: Technology - Services
Type agreement: production manufacturing
Action mechanism:
Disease:
Details: * On March 1, 2016, JHL Biotech announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita’s oncology monoclonal antibodies. The agreement, extending to 2020, is estimated to be worth up to US$20 million in value. JHL will provide cell line development, process development, and manufacturing expertise. The activities will be carried out in JHL's Zhubei site in Taiwan as well as at JHL’s manufacturing facility in Wuhan, China.
Affinita Biotech was founded in 2015 by a group of industry experts to focus on research and development of targeted, immunity based oncology therapies.
Financial terms:
Latest news:
